Volume 3, Issue 3 ( Journal of Clinical and Basic Research (JCBR) 2019)
jcbr 2019, 3(3): 5-11 |
Back to browse issues page
1- Department of Genetics, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
2- Stem Cell Biology Research Center, Yazd Reproductive Science Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
3- Sayad Shirazi Hospital, Golestan Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran
2- Stem Cell Biology Research Center, Yazd Reproductive Science Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
3- Sayad Shirazi Hospital, Golestan Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran
Abstract: (3882 Views)
Backgrounds and objectives: Esophageal squamous cell carcinoma (ESCC) is a prevalent subtype of esophageal cancer in certain areas of the world. Molecular evaluations can provide a better understanding of the disease that could contribute to earlier diagnosis and treatment. Amplification or absence of microRNA (miRNA) genes has been described in many types of cancer, indicating that altered patterns of miRNA expression may affect cell cycle and its features. In this study, we investigated alteration of miR-196a expression in ESCC tissues and its association with tumor status.
Methods: The study was done on 30 specimens including matched tumor and normal tumor margin tissues. RNA extraction and complementary DNA synthesis were performed using specific primers. Quantitative PCR was done to assess the relative expression of miR-196a in tumor tissues of patients with ESCC. Data were normalized by expression level of SNORD gene as an internal control. The GraphPad Prism and SPSS software were used for analysis of data.
Results: MiR-196a expression was higher in cancer tissues compared to normal tissues (P>0.05). The miRNA upregulation had no significant correlation with clinicopathological features such as age, gender and survival rate.
Conclusion: The results of the present study indicate a nonsignificant increased expression of miR-196a in ESCC tumor specimen. Future studies with a larger sample size could confirm our findings.
Methods: The study was done on 30 specimens including matched tumor and normal tumor margin tissues. RNA extraction and complementary DNA synthesis were performed using specific primers. Quantitative PCR was done to assess the relative expression of miR-196a in tumor tissues of patients with ESCC. Data were normalized by expression level of SNORD gene as an internal control. The GraphPad Prism and SPSS software were used for analysis of data.
Results: MiR-196a expression was higher in cancer tissues compared to normal tissues (P>0.05). The miRNA upregulation had no significant correlation with clinicopathological features such as age, gender and survival rate.
Conclusion: The results of the present study indicate a nonsignificant increased expression of miR-196a in ESCC tumor specimen. Future studies with a larger sample size could confirm our findings.
References
1. Lin D-C, Hao J-J, Nagata Y, Xu L, Shang L, Meng X, et al. Genomic and molecular characterization of esophageal squamous cell carcinoma. Nature Genet. 2014;46(5):467. [DOI] [Google Scholar]
2. Chen W, Sun K, Zheng R, Zeng H, Zhang S, Xia C, et al. Cancer incidence and mortality in China, 2014. Chinese journal of cancer research. 2018;30(1):1. [DOI] [Google Scholar]
3. Fukuhara T, Hiyama T, Tanaka S, Oka S, Yoshihara M, Arihiro K, et al. Characteristics of esophageal squamous cell carcinomas and lugol-voiding lesions in patients with head and neck squamous cell carcinoma. J Clin Gastroenterol. 2010;44(2):e27-e33. [DOI] [Google Scholar]
4. Abnet CC, Arnold M, Wei W-Q. Epidemiology of esophageal squamous cell carcinoma. Gastroenterology. 2018;154(2):360-73. [DOI] [Google Scholar]
5. Cho WC. OncomiRs: the discovery and progress of microRNAs in cancers. Mol Cancer. 2007;6(1):60. [DOI] [Google Scholar]
6. Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev. 2006;20(5):515-24. [DOI] [Google Scholar]
7. Jamali L, Tofigh R, Tutunchi S, Panahi G, Borhani F, Akhavan S, et al. Circulating microRNAs as diagnostic and therapeutic biomarkers in gastric and ECs. Journal of cellular physiology. 2018;233(11):8538-50. [DOI] [Google Scholar]
8. Kunej T, Godnic I, Horvat S, Zorc M, Calin GA. Cross talk between microRNA and coding cancer genes. Cancer J. 2012;18(3):223. [DOI] [Google Scholar]
9. Zaravinos A. The regulatory role of microRNAs in EMT and cancer. J Oncol. 2015;2015(2015):13. [DOI] [Google Scholar]
10. Saito Y, Suzuki H, Hibi T. The role of microRNAs in gastrointestinal cancers. J Gastroenterol. 2009;44(19):18-22. [DOI] [Google Scholar]
11. Luthra R, Singh R, Luthra M, Li Y, Hannah C, Romans A, et al. MicroRNA-196a targets annexin A1: a microRNA-mediated mechanism of annexin A1 downregulation in cancers. Oncogene. 2008;27(52):6667-78. [DOI] [Google Scholar]
12. Fendereski M, Zia MF, Shafiee M, Safari F, Saneie MH, Tavassoli M. MicroRNA-196a as a Potential Diagnostic Biomarker for Esophageal Squamous Cell Carcinoma. Cancer Investigation. 2017;35(2):78-84. [DOI] [Google Scholar]
13. Ge J, Chen Z, Li R, Lu T, Xiao G. Upregulation of microRNA-196a and microRNA-196b cooperatively correlate with aggressive progression and unfavorable prognosis in patients with colorectal cancer. Cancer Cell Int. 2014;14(1):128. [DOI] [Google Scholar]
14. Lu Y-C, Chang JT, Liao C-T, Kang C-J, Huang S-F, Chen I-H, et al. OncomiR-196 promotes an invasive phenotype in oral cancer through the NME4-JNK-TIMP1-MMP signaling pathway. Mol Cancer. 2014;13(1):218. [DOI] [Google Scholar]
15. Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nature reviews Drug discovery. 2017;16(3):203. [DOI] [Google Scholar]
16. Huang J, Zhang SY, Gao YM, Liu YF, Liu YB, Zhao ZG, et al. MicroRNAs as oncogenes or tumour suppressors in oEC: potential biomarkers and therapeutic targets. Cell Prolif. 2014;47(4):277-86. [DOI] [Google Scholar]
17. Wang L, Wei Y, Yan Y, Wang H, Yang J, Zheng Z, et al. CircDOCK1 suppresses cell apoptosis via inhibition of miR‑196a‑5p by targeting BIRC3 in OSCC. Oncology reports. 2018;39(3):951-66. [DOI] [Google Scholar]
18. Sun M, Liu X, Li JH, Yang JS, Zhang EB, Yin DD, et al. MiR-196a Is Up-regulated in Gastric cancer and Promotes Cell proliferation by Down-regulating p27kip1. Molecular cancer therapeutics. 2012:molcanther. 1015.2011. [DOI] [Google Scholar]
19. Huang F, Tang J, Zhuang X, Zhuang Y, Cheng W, Chen W, et al. MiR-196a promotes pancreatic cancer progression by targeting nuclear factor kappa-B-inhibitor alpha. PloS one. 2014;9(2):e87897. [DOI] [Google Scholar]
20. Lu Y-C, Chang JT, Liao C-T, Kang C-J, Huang S-F, Chen I-H, et al. OncomiR-196 promotes an invasive phenotype in oral cancer through the NME4-JNK-TIMP1-MMP signaling pathway. Molecular cancer. 2014;13(1):218. [DOI] [Google Scholar]
21. Rajewsky N, Socci ND. Computational identification of microRNA targets. Genome Biology. 2004;5(2):P5. [DOI] [Google Scholar]
22. Hu C, Peng J, Lv L, Wang X, Zhou Y, Huo J, et al. miR 196a regulates the proliferation, invasion and migration of esophageal squamous carcinoma cells by targeting ANXA1. Oncology letters. 2019;17(6):5201-9. [DOI] [Google Scholar]
23. Schimanski CC, Frerichs K, Rahman F, Berger M, Lang H, Galle PR, et al. High miR-196a levels promote the oncogenic phenotype of colorectal cancer cells. World J Gastroenterol. 2009;15(17):2089-96. [DOI] [Google Scholar]
24. Pan Y, Shu X, Sun L, Yu L, Sun L, Yang Z, et al. miR‑196a‑5p modulates gastric cancer stem cell characteristics by targeting Smad4. International journal of oncology. 2017;50(6):1965-76. [DOI] [Google Scholar]
25. Darda L, Hakami F, Morgan R, Murdoch C, Lambert DW, Hunter KD. The role of HOXB9 and miR-196a in head and neck squamous cell carcinoma. PloS one. 2015;10(4):e0122285. [DOI] [Google Scholar]
26. Lu Y-C, Chang JT, Chan E-C, Chao Y-K, Yeh T-S, Chen J-S, et al. miR-196, an emerging cancer biomarker for digestive tract cancers. Journal of Cancer. 2016;7(6):650. [DOI] [Google Scholar]
27. Lu Y-C, Chang JT-C, Huang Y-C, Huang C-C, Chen W-H, Lee L-Y, et al. Combined determination of circulating miR-196a and miR-196b levels produces high sensitivity and specificity for early detection of oral cancer. Clinical biochemistry. 2015;48(3):115-21. [DOI] [Google Scholar]
28. Hui P, Gysler SM, Uduman M, Togun TA, Prado DE, Brambs CE, et al. MicroRNA signatures discriminate between uterine and ovarian serous carcinomas. Human pathology. 2018;76:133-40. [DOI] [Google Scholar]
29. Suh YE, Raulf N, Gäken J, Lawler K, Urbano TG, Bullenkamp J, et al. MicroRNA‐196a promotes an oncogenic effect in head and neck cancer cells by suppressing annexin A1 and enhancing radioresistance. International journal of cancer. 2015;137(5):1021-34. [DOI] [Google Scholar]
30. Schimanski CC, Frerichs K, Rahman F, Berger M, Lang H, Galle PR, et al. High miR-196a levels promote the oncogenic phenotype of colorectal cancer cells. World journal of gastroenterology: WJG. 2009;15(17):2089. [DOI] [Google Scholar]
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |